6,544 followers
New research: Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase: The treatment of chronic myeloid leukemia (CML) has been advanced by the development of… https://t.co/niLzhOK8UA